ArticleHeadache
Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study.
Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.Clinical pharmacology and therapeutics · 2026Article
- Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.Headache · 2026Article
- Impact of semaglutide introduction on the use of triptans: an interrupted-time series.The journal of headache and pain · 2026Article
- Therapeutic and research frontiers in fibromyalgia: integrating pathophysiology with innovative drug repurposing.Inflammopharmacology · 2026Review
- Acupuncture modulates migraine-related neural and neuroendocrine regulatory pathways.The journal of headache and pain · 2026Review
- G2DR: a genotype-first framework for genetics-informed target prioritization and drug repurposing.Briefings in bioinformatics · 2026Article
- Integrating Nutrition and Physical Activity into the EXEMIG/01 Interdisciplinary Model for Chronic and High-Frequency Migraine.Nutrients · 2026Article
- Association between headache and hearing impairment in middle-aged and older adults in China health and retirement longitudinal study.Scientific reports · 2026Article
- Impact of bariatric surgery on headache frequency and severity and quality of life in patients with migraine: a prospective study.BMJ neurology open · 2026Article
- Papilledema is not the point: intracranial pressure dysregulation as a common pathway in migraine and idiopathic intracranial hypertension.Brain communications · 2026Article
- The expanding landscape of GLP-1 medicines.Nature medicine · 2026Review
- Glucagon-like peptide-1 medicines in neurological and psychiatric disorders.Cell reports. Medicine · 2025Review
- Idiopathic intracranial hypertension without papilledema in chronic migraineurs and revisiting of friedman's diagnostic criteria.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess whether glucagon-like-peptide-1 receptor (GLP-1R) agonists could serve as a novel prophylactic treatment for migraine in patients with obesity.
backgroundIncreased intracranial pressure (ICP) is speculated to play a role in migraine mechanisms, as chronic migraine and idiopathic intracranial hypertension without papilledema (IIWHOP) are often clinically indistinguishable. These striking similarities suggest a deep pathogenetic link between the two conditions posing the hypothesis that control of ICP may be helpful in migraine treatment. The GLP-1R agonists have been shown to greatly reduce ICP. Notably, they have also been demonstrated to decrease calcitonin gene-related peptide expression in chronic migraine models.
methodsThis was a prospective, interventional, open-label, pilot cohort study, evaluating the effectiveness of liraglutide as an add-on treatment of unresponsive migraine in patients with obesity. We consecutively enrolled patients with high-frequency or chronic migraine and a body mass index (BMI) of >30 kg/m
resultsWe enrolled 31 patients (26 females, five males, with a mean [standard deviation, SD] age of 44.9 [14.6] years). The mean (SD) monthly days with headache decreased from 19.8 (6.7) to 10.7 (7.7) days post-treatment. This change was significant with a mean difference of 9.1 days (95% confidence interval [CI] 5.41-12.84, p < 0.001, Cohen's d: 0.90). Conversely, BMI decreased slightly from a mean (SD) of 34.0 (2.3) to 33.9 (2.3) kg/m
conclusionOur findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity, and that this effect is independent from weight loss. Although further studies are needed to clarify this topic, these findings generate the hypothesis that a derangement in ICP control may play a role in migraine pathogenesis and potentially represent a novel therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.